CD40 Ligand (CD40L) Antibody Market Report 2026

CD40 Ligand (CD40L) Antibody Market Overview

• CD40 Ligand (CD40L) Antibody market size has reached to $0.69 billion in 2025 • Expected to grow to $1.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.9% • Growth Driver: Impact Of Rising Autoimmune Disorders On Therapeutic Advancements • Market Trend: Advancements In CD40L Antibody Therapies And Xenotransplantation Clinical Trials • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under CD40 Ligand (CD40L) Antibody Market?

CD40 ligand (CD40L) antibody is a therapeutic agent targeting the CD40L protein to block CD40-CD40L interactions, modulating immune responses for applications in autoimmune diseases, transplant rejection, and cancer immunotherapy. It modulates the immune system by blocking the interaction between CD40L and CD40, which is crucial in immune activation. The main types in the cd40 ligand (cd40l) antibody are monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies originate from a single cell clone and are designed to target a specific epitope on an antigen. These antibodies are utilized in applications such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), western blotting, immunoprecipitation, immunofluorescence, and other applications. Various end-users include hospitals, research institutes, specialty clinics, and various other users.

What Is The CD40 Ligand (CD40L) Antibody Market Growth Forecast?

The cd40 ligand (cd40l) antibody market size is expected to see strong growth in the next few years. It will grow to $1.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to growth in immunotherapy pipelines, rising transplant procedures, expansion of targeted immune therapies, increasing clinical trial activity, growing biotech investments. Major trends in the forecast period include growing research in immune modulation therapies, increasing development of monoclonal cd40l antibodies, rising focus on autoimmune and transplant indications, expansion of preclinical and clinical studies, increased collaboration between pharma and research institutes.

What Is The Driver Of The CD40 Ligand (CD40L) Antibody Market?

The rising incidences of autoimmune disorders are expected to drive the growth of the CD40 ligand (CD40L) antibody market going forward. Autoimmune disorders occur when the immune system attacks the body's cells, causing damage, including rheumatoid arthritis, lupus, and type 1 diabetes. The rising prevalence of autoimmune disorders can be attributed to factors such as environmental triggers, genetic predisposition, lifestyle changes, and an increase in diagnostic awareness, which collectively contribute to a higher rate of detection and occurrence. CD40 Ligand (CD40L) antibodies are emerging as a potential therapeutic approach for treating autoimmune disorders by modulating the immune system's overactive response. For instance, in May 2023, according to the University of Oxford, a UK-based research university, autoimmune disorders affect about one in ten individuals, with 13% of women and 7% of men impacted across 19 studied autoimmune diseases. Therefore, the rising incidences of autoimmune disorders drive the growth of the CD40 ligand (CD40L) antibody industry.

Key Players In The Global CD40 Ligand (CD40L) Antibody Market

Major companies operating in the cd40 ligand (cd40l) antibody market are Thermo Fisher Scientific Co. Ltd., Amgen Inc., Bio-Rad Laboratories Inc., Bio-Techne Corporation, Kiniksa Pharmaceuticals Ltd., BioLegend, Cytek Biosciences Inc., Sino Biological Inc., ACROBiosystems, Elabscience Biotechnology Inc., Cayman Chemical, Eledon Pharmaceuticals, Cell Signaling Technology, Enzo Biochem, GeneTex, GeminiBio, Creative Biolabs, BPS Bioscience Inc., LSBio, MyBiosource Inc., Boster Biological Technology, Bio X Cell, Assay Genie, Abeomics, Leinco Technologies Inc.

Global CD40 Ligand (CD40L) Antibody Market Trends and Insights

Major companies operating in the CD40 ligand (CD40L) antibody market are focusing on advancing clinical trials and expanding therapeutic applications, such as CD40L-targeted immunomodulated xenotransplantation to enhance graft survival in genetically modified porcine-to-human heart transplantation. CD40L-targeted immunomodulated xenotransplantation refers to the process of transplanting organs, tissues, or cells between different species while specifically using therapies that inhibit the CD40 ligand (CD40L) pathway to modulate the recipient’s immune response, reduce organ rejection, and improve graft survival. For instance, in September 2023, Eledon Pharmaceuticals Inc., a US-based biotechnology company, announced using Tegoprubart anti-CD40L antibody in a clinical trial following the second-ever genetically modified pig heart transplant, the trial aimed to assess its role in preventing organ rejection and expanding therapeutic applications in organ transplantation. Tegoprubart has also shown potential in treating autoimmune diseases by modulating immune responses.

What Are Latest Mergers And Acquisitions In The CD40 Ligand (CD40L) Antibody Market?

In January 2023, eGenesis Inc., a US-based biotechnology company, partnered with Eledon Pharmaceuticals Inc. The partnership will enable eGenesis to incorporate Eledon’s anti-CD40L antibody, tegoprubart, into its preclinical research for developing human-compatible organs and cells for transplantation. Eledon Pharmaceuticals Inc. is a US-based biotechnology company specializing in developing novel immunotherapies.

What Defines the CD40 Ligand (CD40L) Antibody Market?

The CD40 ligand (CD40L) antibody market consists of revenues earned by entities by providing services such as custom antibody development, recombinant antibody engineering, antibody purification, and functional assays and validation. The market value includes the value of related goods sold by the service provider or included within the service offering. The CD40 ligand (CD40L) antibody market includes sales of infusion pumps and monoclonal antibody testing systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the CD40 Ligand (CD40L) Antibody Market Report 2026?

The cd40 ligand (cd40l) antibody market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cd40 ligand (cd40l) antibody industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.